BKM120 (NVP-BKM120, Buparlisib)

Catalog No. A11016

BKM120 (NVP-BKM120,Buparlisib)是生物可利用的口服泛I类磷脂酰肌醇3激酶(PI3K)激酶抑制剂,在无细胞试验中作用于p110α/β/δ/γ的。对VPS34,mTOR,DNAPK的作用效果下降,而对 PI4Kβ几乎没有活性。
  • Giri R. Gnawali, .et al. Synthesis of 2-oxoquinoline derivatives as dual pim and mTORC protein kinase inhibitors, Medicinal Chemistry Research, 2022, 31: 1154-1175
  • Yusuke Murase, .et al. Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells, Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890
  • Jeremiah J Bearss, .et al. EDC3 phosphorylation regulates growth and invasion through controlling P-body formation and dynamics, EMBO Rep, 2021, Apr 7;22(4):e50835 PMID: 33586867
  • Takaaki Fujimura, .et al. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells, Cancer Biol Ther, 2020, Sep 1;21(9):863-870 PMID: 32835580
  • Nachi Namatame, .et al. Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines, Oncotarget, 2018, Oct 12; 9(80): 35141-35161 PMID: 30416685
  • Jin H. Song, .et al. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase, Mol Cancer Ther, 2018, Dec;17(12):2710-2721 PMID: 30190422
  • Saijo A, .et al. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells, Cancer Lett, 2018, May 1;421:17-27 PMID: 29448000
  • Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
  • Pridham KJ, .et al. PIK3CB/p110β is a selective survival factor for glioblastoma, Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
  • Charles-André Philip, .et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors, BMC Cancer, 2017, 17: 638 PMID: 28886696
  • Rogers HA, .et al. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival., Clin Cancer Res., 2013, Dec 1;19(23):6450-60 PMID: 24077346
Catalog Num A11016
M. Wt 410.4
Formula C18H21F3N6O2
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 944396-07-0
Synonyms
SMILES C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
BKM120 (NVP-BKM120,Buparlisib)是生物可利用的口服泛I类磷脂酰肌醇3激酶(PI3K)激酶抑制剂,在无细胞试验中作用于p110α/β/δ/γ的。对VPS34,mTOR,DNAPK的作用效果下降,而对 PI4Kβ几乎没有活性。
Targets
Target Value
p110αIC50: 52nM
p110δIC50: 116nM
p110βIC50: 166nM
p110γIC50: 262nM
Vps34IC50: 2.4μM
mTORIC50: 4.6μM
DNA-PKIC50: >5μM
PI4KβIC50: >25μM
In vitro (25°C) DMSO 76 mg/mL (185.18 mM)
Water Insoluble
Ethanol 2 mg/mL (4.87 mM)
In vivo 5% DMSO+30% PEG 300+ddH2O 14 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 24.37 mL 121.83 mL 243.66 mL
0.5 mM 4.87 mL 24.37 mL 48.73 mL
1 mM 2.44 mL 12.18 mL 24.37 mL
5 mM 0.49 mL 2.44 mL 4.87 mL

*The above data is based on the productmolecular weight 410.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.